Gilad Oren's Form 4 filing
Aprea Therapeutics, Inc. (APRE) · filed Dec 11, 2025
- Accession no.
- 0001104659-25-120152
- Filed
- Dec 11, 2025
- Trade date
- Dec 10, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 0 non-derivative transactions and 2 derivative transactions. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gilad OrenCIK 0001929300 | Director, Officer (President/CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 10, 2025 | Common Stock | PPurchaseAcquired | +21,459 | $1.17 | +$25,107.03 | 21,459 | Direct | |
| Dec 10, 2025 | Common Stock | PPurchaseAcquired | +21,459 | – | – | 21,459 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.